BGB-A317-303

Completed

Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

Beigene Study ID info

BGB-A317-303

ClinicalTrials.gov ID info

EudraCT Number info

2018-000245-39

China Drug Trials ID info

CTR20171112

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan